By merging precision genetic engineering with the scalability of nanomedicine and the predictive power of AI, scientists are reshaping the future of human health.
- Why A Cell Therapy CEO Waited Until Phase III To Outsource
- Field Notes: APEC RHSC's Workshop On ATMP Development And Evaluation
- U.S. Pharma Tariffs And MFN Become Law After April 2 Update
- How To Implement Post-Approval Changes On A Global Level
- March 2026 — CDMO Opportunities And Threats Report
- Target Selection Drives The Future Of CAR T Therapy In Solid Tumors
- Mastering Biotech's Insourcing/Outsourcing Trade-Offs
- From Principles To Practice: Building Quality Into Generative AI-Assisted Pharma Operations
CELL & GENE ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Liquid Biopsy-Based Detection Of PIK3CA Mutations From cfDNA
Discover how ultra-sensitive digital PCR workflows use an innovative system to enable precise detection of rare PIK3CA mutations in cfDNA and advance personalized cancer treatment.
-
Expanding Translational Research Concepts With Genedata Profiler
The biopharma industry leverages Genedata Profiler to integrate, curate, and analyze diverse R&D data, enabling collaborative, compliant, and AI-driven translational research to optimize drug development.
-
The Need For Adaptive Distribution Partners For Cell And Gene Therapies
Optimize your commercial strategy by exploring how adaptive distribution models navigate reimbursement challenges and improve patient access. Partner early to align workflows and ensure operational success.
-
The Value Of Peptones For Cost-Effective Vaccine Manufacturing
Peptones offer a strategic solution to key biomanufacturing challenges by enhancing cell culture performance, improving yields, and reducing production costs.
-
Sensitive RNA Fluorescent Quantitation With An RNA Assay Kit
Accurate nucleic acid quantification is vital for applications like PCR and NGS. Discover an RNA Assay Kit that offers precise RNA measurement to enhance reliability and performance in downstream assays.
-
The True ROI Of Decentralized Clinical Trials
Gain a greater understanding of how the right DCT solution, or combination of solutions, coupled with clear metrics and expert guidance on execution, can demonstrate tangible, quantitative ROI in clinical trials.
-
The Importance Of Quality In Raw Material Selection
Learn how to select high-quality raw materials for cell-based manufacturing in this exploration of the criticality of raw materials, from preclinical development to commercialization.
-
Navigating The CGT Landscape: Key Takeaways From The FDA's New FAQ
The FDA's new FAQ on cell and gene therapy offers a roadmap for developers. Review key insights from the document, including the importance of early engagement with the FDA, CMC considerations, and more.
-
High-Throughput Lipid Separation For LNP Formulations
Lipid nanoparticles (LNPs) carry immense potential as delivery systems. Learn about the development of isocratic and gradient methods for high-throughput separation of lipids used in LNP formulations.
-
Control Strategies And Method Development For Nitrosamines In APIs And Drug Products
Explore regulatory insights, analytical strategies, and real-world case studies for effective nitrosamine control in APIs and drug products.
NEWSLETTER ARCHIVE
- 04.20.26 -- Why A Cell Therapy CEO Waited Until Phase III To Outsource
- 04.17.26 -- Large Molecule Capacity Powering Cell & Gene Therapies
- 04.17.26 -- Building Smarter Cell Therapies With AI And Synthetic Biology
- 04.16.26 -- Cell & Gene Capabilities That You Need to Know
- 04.16.26 -- Prioritizing Quality, Fit, And Supplier Reliability In CGT Materials
CELL AND GENE CONTENT COLLECTIONS
While there are opportunities to scale, there are also manufacturing gaps, capacity issues, and production timelines that require improvement to do so. And then, of course, there’s cost. Because scale up and scale out are significant to everyone in the sector, we’ve curated insightful editorial that addresses the most important aspects of scalability.
More Content Collections